2001
DOI: 10.1590/s1413-86702001000300004
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: This study aimed at evaluating the efficacy and safety of meropenem as first choice treatment for nosocomial pneumonia (NP) in intensive care units (ICU) in Hospital das Clínicas (HC) - University of São Paulo; a hospital with high incidence of antimicrobial resistance. Prospective, open, and non-comparative trial with meropenem were done in patients with ventilator-associated or aspiration NP in 2 ICUs at HC - University of São Paulo. Etiologic investigation was done through bronchoalveolar lavage and blood c… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
3
0
1

Year Published

2008
2008
2020
2020

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(4 citation statements)
references
References 12 publications
0
3
0
1
Order By: Relevance
“…A smaller prospective, open-label, noncomparative clinical trial investigated the efficacy of the same meropenem regimen in 25 patients у18 years of age with VAP (76% of the population) or aspiration nosocomial pneumonia (24% of the population) in a hospital with a high prevalence of antimicrobial-resistant bacteria. The clinical response rate was 76% at the end of treatment and 48% at follow-up [43]. In infants with nosocomial pneumonia caused by multidrug-resistant Acinetobacter baumannii or K. pneumoniae ( ), meropenem at 20 mg/kg every 8 h (every 12 h for n p 32 the first week of life in preterm infants) achieved clinical and bacteriological response rates at the end of treatment of 87.5% in a prospective, noncomparative clinical trial [44].…”
Section: Efficacymentioning
confidence: 98%
“…A smaller prospective, open-label, noncomparative clinical trial investigated the efficacy of the same meropenem regimen in 25 patients у18 years of age with VAP (76% of the population) or aspiration nosocomial pneumonia (24% of the population) in a hospital with a high prevalence of antimicrobial-resistant bacteria. The clinical response rate was 76% at the end of treatment and 48% at follow-up [43]. In infants with nosocomial pneumonia caused by multidrug-resistant Acinetobacter baumannii or K. pneumoniae ( ), meropenem at 20 mg/kg every 8 h (every 12 h for n p 32 the first week of life in preterm infants) achieved clinical and bacteriological response rates at the end of treatment of 87.5% in a prospective, noncomparative clinical trial [44].…”
Section: Efficacymentioning
confidence: 98%
“…Esses fatores, unidos ao fato de se ter a cada dia um crescimento no número de pacientes debilitados quer pela idade ou por alguma doença, vêm justificar a necessidade da correta utilização de antibióticos bem como de criteriosos exames clínicos e microbiológicos. [28][29] Como procedimento de minimizarem infecções nosocomiais, a equipe de saúde de um hospital geral privado de Brasília (DF) adotou algumas medidas como a elevação da cabeceira do leito entre 30 ° a 45 ° para os pacientes que apresentavam alto risco para pneumonia por aspiração; tocar no paciente e seus utensílios apenas quando necessário, lavar as mãos antes e após os procedimentos, usar adequadamente luvas, máscaras e capotes. Somadas a essas ações, houve a implantação de uma maior racionalização do uso de antimicrobianos, obtendo bons resultados na diminuição da taxa de infecções e nos gastos hospitalares.…”
Section: Método Resultadosunclassified
“…Meningitis can be brought about by a bacterial, parasitic or viral disease. Meningitis can be intense, with a brisk beginning of manifestations, it very well may be incessant, enduring a month or much more, or it tends to be gentle or aseptic (Santos et al, 2001).The common side effects are head ache, vomiting, nausea, twinge, rashes, and also pain at the site of the injection (Lerma and Group, 2001). The considerable side effects will include clostridium dif icile injection, anaphylaxis allergy, and also seizures (Schmutzhard et al, 1995).…”
Section: Introductionmentioning
confidence: 99%